BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

BridgeBio reported Q2 Attruby sales of $222M+ after FDA approval for ATTR-CM in late 2024, nearly tripling year over year from $71.5M (its first full quarter on the market), lifting total Q2 revenue to ~$244M vs nearly $111M in Q2 2025. The company also submitted NDAs for three late-stage programs in the quarter, with two accepted for FDA review. Piper Sandler raised its price target while keeping an “overweight” rating, expecting BBP-418 to gain approval with a Nov. 27 PDUFA decision date, potentially enabling revenue by end-2026.

Analysis

BridgeBio is starting to look less like a pure binary biotech and more like a two-leg story: a commercial asset that can fund itself and a pipeline that can re-rate the equity if even one more program clears the line. The market will initially reward top-line acceleration, but the bigger variable is durability of gross-to-net; if access gets bought via higher rebates, apparent revenue strength will overstate true economics and the multiple should compress.

The competitive read-through is more important than the company framing. Strong adoption in ATTR-CM can pressure incumbents to defend share with concessions, which helps patients but usually lowers the ceiling for everyone in the class; the better trade may be on who can absorb that pressure with the least margin damage. If BridgeBio can keep formulary access while expanding physician familiarity in rare cardiology, it improves launch odds for the rest of the pipeline and reduces the probability of a dilutive equity raise over the next 6-12 months.

The next hard catalyst is the late-November FDA decision, but the real stock reaction will depend on whether management can convert approval risk into a credible 2026 revenue bridge. Consensus may be overestimating the persistence of launch growth from a small base; these curves often look explosive for 2-3 quarters and then normalize once the easiest patients are captured. The thesis breaks if sequential prescriptions decelerate, if payer pushback lifts rebates, or if the FDA asks for more data on the lead pipeline asset.

Key Decisions for Investors

• Long BBIO on pullbacks into the Nov. 27 PDUFA window; use a 1-3 month horizon and keep size modest because the stock is still driven by execution and regulatory binary risk. Thesis is validated if quarterly net sales hold above the low-$200M range with stable gross-to-net.
• Pair trade: long BBIO / short XBI for the next 4-8 weeks to isolate single-name commercial and FDA catalyst alpha from sector beta. Falsify if the move is clearly just biotech risk-on and BBIO underperforms the index on positive company-specific data.
• For higher-risk accounts, buy BBIO call spreads expiring after the PDUFA event rather than outright calls; this caps premium paid if the market has already priced in approval. Best used only if implied volatility is not already extreme.
• Watch PFE and ALNY as competitive pressure proxies: if either starts discounting harder or guiding to slower ATTR-CM growth, it signals BBIO’s launch is forcing class-wide margin compression and the stock’s revenue quality is improving.